Brought to you by 
Novartis gets option to small-molecule drugs from Ascent
04 Oct 2011
Executive Summary
Ascent Therapeutics (developing drug candidates that focus on G protein-coupled receptors) has agreed to use its Pepducin technology to discover and develop compounds against an undisclosed GPCR target to which Novartis gets a licensing option.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Novartis gets option to small-molecule drugs from Ascent
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice